Bloomberg Law
Health Law & Business
LinkedIn

Regeneron Pharma Sees Charge of About $56m on Sonoma Bio Pact

April 10, 2023, 11:14 AM UTC
Georgi Azar
Georgi Azar

Regeneron Pharmaceuticals expects to incur an acquired IPR&D charge of about $56m on a pre-tax basis in 1Q 2023, related to an up-front payment for its collaboration and license agreement with Sonoma Biotherapeutics.

  • Charge is expected to negatively impact each of GAAP and non-GAAP net income per diluted share for 1Q by about $0.42

To view the source of this information, click here

To contact the reporter on this story:
Georgi Azar in New York at gazar4@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net

© 2023 Bloomberg L.P. All rights reserved. Used with permission.

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.